| Primary |
| Chronic Myeloid Leukaemia |
72.3% |
| Gastrointestinal Stromal Tumour |
17.6% |
| Acute Lymphocytic Leukaemia |
3.7% |
| Hypertension |
1.6% |
| Diabetes Mellitus |
0.5% |
| Blast Crisis In Myelogenous Leukaemia |
0.5% |
| Pulmonary Arterial Hypertension |
0.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
0.4% |
| Scleroderma |
0.3% |
| Chronic Myeloid Leukaemia Transformation |
0.3% |
| Hypereosinophilic Syndrome |
0.3% |
| Prophylaxis |
0.3% |
| Pyrexia |
0.3% |
| Type 1 Diabetes Mellitus |
0.3% |
| Acute Myeloid Leukaemia |
0.2% |
| Depression |
0.2% |
| Gastric Ulcer |
0.2% |
| Gastritis |
0.2% |
| Gastrooesophageal Reflux Disease |
0.2% |
| Graft Versus Host Disease |
0.2% |
|
| Death |
77.7% |
| Second Primary Malignancy |
2.5% |
| Malignant Neoplasm Progression |
2.2% |
| Thrombocytopenia |
2.1% |
| Vomiting |
1.7% |
| White Blood Cell Count Increased |
1.6% |
| Pneumonia |
1.4% |
| Anaemia |
1.3% |
| Pyrexia |
1.2% |
| Sepsis |
1.1% |
| Neoplasm Progression |
1.0% |
| White Blood Cell Count Decreased |
0.9% |
| No Therapeutic Response |
0.8% |
| Therapeutic Response Decreased |
0.8% |
| Drug Ineffective |
0.7% |
| Pancytopenia |
0.7% |
| Circulatory Collapse |
0.6% |
| Platelet Count Decreased |
0.6% |
| Splenomegaly |
0.6% |
| Septic Shock |
0.6% |
|
| Secondary |
| Chronic Myeloid Leukaemia |
54.6% |
| Gastrointestinal Stromal Tumour |
15.2% |
| Product Used For Unknown Indication |
5.8% |
| Acute Lymphocytic Leukaemia |
4.3% |
| Acute Myeloid Leukaemia |
3.0% |
| Hypertension |
2.9% |
| Pulmonary Arterial Hypertension |
2.8% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.5% |
| Scleroderma |
1.5% |
| Gastric Ulcer |
1.3% |
| Prophylaxis |
1.0% |
| Gastritis |
0.9% |
| Right Ventricular Failure |
0.8% |
| Graft Versus Host Disease |
0.7% |
| Oedema |
0.7% |
| Pyrexia |
0.7% |
| Blast Crisis In Myelogenous Leukaemia |
0.6% |
| Chronic Myeloid Leukaemia Transformation |
0.5% |
| Depression |
0.5% |
| Gastrointestinal Neoplasm |
0.4% |
|
| Death |
26.6% |
| White Blood Cell Count Increased |
11.7% |
| Malignant Neoplasm Progression |
8.9% |
| Second Primary Malignancy |
6.3% |
| Vomiting |
6.3% |
| Thrombocytopenia |
6.1% |
| White Blood Cell Count Decreased |
5.4% |
| Therapeutic Response Decreased |
4.5% |
| Drug Ineffective |
3.5% |
| Pyrexia |
3.0% |
| Weight Decreased |
2.8% |
| No Therapeutic Response |
2.4% |
| Myocardial Infarction |
2.2% |
| Platelet Count Decreased |
1.9% |
| Neoplasm Recurrence |
1.7% |
| Respiratory Failure |
1.5% |
| Neoplasm Progression |
1.3% |
| Neutropenia |
1.3% |
| Pneumonia |
1.3% |
| Rash Generalised |
1.3% |
|
| Concomitant |
| Chronic Myeloid Leukaemia |
17.3% |
| Prophylaxis |
14.4% |
| Acute Lymphocytic Leukaemia |
8.7% |
| Graft Versus Host Disease In Intestine |
5.8% |
| Immunosuppressant Drug Therapy |
5.8% |
| Prophylaxis Against Graft Versus Host Disease |
5.8% |
| Graft Versus Host Disease |
4.8% |
| Hypertension |
4.8% |
| Gastrointestinal Stromal Tumour |
3.8% |
| Pulmonary Hypertension |
3.8% |
| Agitation |
2.9% |
| Chemotherapy |
2.9% |
| Chromosome Analysis Abnormal |
2.9% |
| Hyperuricaemia |
2.9% |
| Product Used For Unknown Indication |
2.9% |
| Right Heart Failure |
2.9% |
| Anxiety |
1.9% |
| Aspergillus Test Positive |
1.9% |
| Atrial Fibrillation |
1.9% |
| Hyperlipidaemia |
1.9% |
|
| Septic Shock |
10.7% |
| Wound Decomposition |
10.7% |
| Disseminated Intravascular Coagulation |
7.1% |
| Lipase Increased |
7.1% |
| Retinal Detachment |
7.1% |
| Vertigo |
7.1% |
| Angina Unstable |
3.6% |
| Cardiac Failure |
3.6% |
| Hyponatraemia |
3.6% |
| Joint Swelling |
3.6% |
| Lung Disorder |
3.6% |
| Pain In Extremity |
3.6% |
| Pain In Jaw |
3.6% |
| Peripheral Arterial Occlusive Disease |
3.6% |
| Rash |
3.6% |
| Rectal Haemorrhage |
3.6% |
| Renal Impairment |
3.6% |
| Sialoadenitis |
3.6% |
| Skin Induration |
3.6% |
| Somnolence |
3.6% |
|
| Interacting |
| Acute Lymphocytic Leukaemia |
33.3% |
| Chronic Myeloid Leukaemia |
33.3% |
| Parkinson's Disease |
33.3% |
|
| Drug Interaction |
33.3% |
| Oedema |
33.3% |
| Rhabdomyolysis |
33.3% |
|
